Next Article in Journal
Molecular Characterization and Functional Analysis of Odorant-Binding Proteins in Ectropis grisescens
Previous Article in Journal
Liensinine Prevents Acute Myocardial Ischemic Injury via Inhibiting the Inflammation Response Mediated by the Wnt/β-Catenin Signaling Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 10
10.3390/ijms26104567
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients

by
Anna Gorący-Rosik
1,
Mateusz Fic
1,
Jakub Rosik
2,
Klaudyna Lewandowska
1,
Krzysztof Safranow
3,
Andrzej Ciechanowicz
1,* and
Iwona Gorący
1
1
Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
2
Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
3
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(10), 4567; https://doi.org/10.3390/ijms26104567
Submission received: 8 April 2025 / Revised: 6 May 2025 / Accepted: 7 May 2025 / Published: 10 May 2025
(This article belongs to the Section Molecular Genetics and Genomics)
Versions Notes

Abstract

:
Heart failure (HF) is a complex disease and a major cause of morbidity and mortality worldwide. Natriuretic peptides (NPs) are involved in the pathogenesis of HF, but their activity may be modified by polymorphisms in the genes encoding them. Aim: To examine the associations of NPPA:rs5065 and NPPB:rs198389 polymorphisms with the risk of HF and cardiovascular phenotypes in Polish patients with HF. The study group comprised 330 HF patients, and the control group comprised 206 healthy newborns. Genomic DNA was extracted from blood, and genotyping of both polymorphisms was performed using polymerase chain reaction–restriction fragment length polymorphism. There were no significant differences in the distributions of NPPA and NPPB genotypes between HF patients and controls. Within the HF group, there were no significant associations between the frequencies of type 2 diabetes, hypertension, left ventricular hypertrophy, or categories of left ventricular ejection fraction (LVEF) and the NPPA or NPPB variants. However, LVEF was significantly higher in NPPA CC homozygotes than in carriers of at least one T allele. The results of our study did not confirm an association between the NPPA:rs5065 or NPPB:rs198389 polymorphisms and predisposition to HF or HF intermediate phenotypes, except for LVEF.

1. Introduction

Heart failure (HF) is a complex disease and a major cause of morbidity and mortality worldwide [1]. In 2017, more than 64 million people suffered from HF globally, and its prevalence is expected to continue rising [2]. According to a universal consensus introduced in 2021, HF is defined as a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality, corroborated by elevated natriuretic peptide (NP) levels and/or objective evidence of pulmonary or systemic congestion [2,3]. Additionally, based on the left ventricular ejection fraction (LVEF), Bozkurt et al. [3] proposed classifying HF into three LVEF categories: HF with a reduced ejection fraction (HFrEF), defined as symptomatic HF with an LVEF of ≤40%; HF with a mildly reduced ejection fraction (HFmrEF), defined as symptomatic HF with an LVEF of 41% to 49%; and HF with a preserved ejection fraction (HFpEF), defined as symptomatic HF with an LVEF of ≥50%. The major causes of HF include coronary artery disease (CAD), arterial hypertension, heart valve disease, and cardiomyopathy [1].
The pathogenesis of HF is complex and primarily involves activation of the renin-angiotensin–aldosterone system and sympathetic nervous system, followed by activation of natriuretic peptides (NPs), which exert antagonistic effects against the increased activities of these systems [4,5,6]. Recently, Kuwahara [6] reviewed the role of atrial NP (ANP) and brain (or B-type) NP (BNP), which are physiologically abundant and secreted in the atria and ventricles, respectively. These NPs are of particular interest in the context of HF because of their cardioprotective effects and their increased concentrations in patients with HF [6].
The ANP or BNP precursors (preproANP or preproBNP, respectively) are encoded in humans by the NPPA and NPPB paralogous genes, which are located 9118 base pairs apart on chromosome 1q36 [7]. The NPPA:rs5065 polymorphism is a c.2238T>C transition that abolishes the regular stop codon (TGA). Analysis of the NPPA gene sequence predicts that this nonstop mutation results in an extension of preproANP translation by two additional arginines, leading to the production of mature ANP (alpha-carboxy-terminal peptide) consisting of 30 amino acids instead of 28 [8]. Rubattu et al. revealed that, in vitro, such synthetic 30-amino-acid-long ANP exerts deleterious biological effects, including increased generation of reactive oxygen species, endothelial damage, contraction of vascular smooth muscle cells, and platelet aggregation [8,9]. However, to the best of our knowledge, no reports to date have confirmed the presence of ANP with two additional arginines in vivo in humans. It is also worth noting that, as early as 1984, Greenberg et al. [10] identified these two arginines as a potential proteolytic site.
Few reports concerning the association of the NPPA:rs5065 polymorphism with the concentration of plasma ANP have been published, and their results appear to be conflicting [11,12,13,14,15,16]. Kato et al. [11] reported no association between the plasma ANP level and the NPPA:rs5065 polymorphism in 102 healthy normotensive Japanese subjects. An age- and sex-adjusted analysis conducted by Cannone et al. [12] in a random community-based sample of 1623 subjects also revealed no differences in plasma ANP concentrations regarding the NPPA:rs5065 polymorphism. However, they observed that the minor c.2238C allele was significantly associated with higher BNP levels in plasma [12]. On the other hand, Nannipieri et al. [13] found in a homogeneous cohort of normotensive patients with type 1 diabetes that plasma ANP levels in wild-type NPPA:rs5065 homozygous subjects (TT homozygotes) were significantly higher than those in c.2238T>C heterozygotes. By contrast, we found in Polish individuals with salt-sensitive hypertension that plasma ANP concentrations on a normal- or high-sodium diet were significantly higher in carriers of the NPPA:rs5065 minor allele (c.2238C variant) than in wild-type homozygotes [14]. Similarly, Vassalle et al. reported that, among patients with New York Heart Association (NYHA) class III to IV HF, carriers of the risk allele (CT + CC) had higher ANP concentrations than wild-type NPPA:rs5065 homozygotes (TT homozygotes) [15].
Despite no clear evidence for the association of NPPA:rs5065 with this intermediate phenotype, the results of a recent meta-analysis based on 12 studies involving more than 45,500 patients from different ethnic groups suggest that the c.2238T>C NPPA transition increases the risk of myocardial infarction, cerebrovascular events, and composite cardio-cerebral vascular events [16]. However, the results of another meta-analysis based on 13 case-control studies involving more than 7000 subjects suggested no significant association between the NPPA:rs5065 polymorphism and the risk of essential hypertension in various ethnic groups (Tunisia, China, Slovenia, Japan, Italy, and African Americans) [17].
The NPPB:rs198389 (c.-381T>C) promoter polymorphism is a functional variant that disrupts a transcriptionally active enhancer box, and the c.-381T>C transition is associated with a 1.8-fold higher level of promoter activity in vitro compared with the wild-type T allele [18,19]. The mutated c.-381C NPPB allele (minor allele) has been consistently associated with elevated mean levels of NT-proBNP and/or BNP in various ethnic groups [19,20,21,22,23], including studies that used genome-wide genotyping [24,25,26,27,28,29] or genome-wide sequencing [30]. On the other hand, Seidelmann et al. revealed in patients (n = 11,361 African Americans and whites) from the Atherosclerosis Risk in Communities (ARIC) study that the NPPB:rs198389 minor allele (c.-381C allele) was not only associated with elevated NT-proBNP levels throughout adult life but also with reduced blood pressure, a reduced risk of hypertension and cardiovascular mortality, and an increased lifespan [18]. Similarly, Cannone et al. in 971 patients with cardiovascular risk factors but without symptomatic HF from the St Vincent’s Screening to Prevent Heart Failure (STOP-HF) follow-up study, found that the c.-381C NPPB allele was associated with higher circulating levels of BNP and a favorable clinical phenotype and outcome, characterized by a lower risk of hypertension, new-onset left ventricular systolic dysfunction, and major adverse cardiovascular events [31].
Therefore, the aim of our study was to analyze the associations of NPPA:rs5065 and NPPB:rs198389 polymorphisms in Polish patients with HF with the risk of HF, as well as with cardiovascular phenotypes, including type 2 diabetes mellitus (T2DM), hypertension, left ventricular mass (LVM), and LVEF.

2. Results

The NPPA:rs5065 and NPPB:rs198389 genotype distributions in the HF group or in control newborns conformed to the expected Hardy–Weinberg equilibrium (p = 0.096 and p = 0.557 or p = 0.237 and p = 0.271, respectively).
For the NPPA:rs5065 (c.2238T>C) polymorphism, among the 85 women with HF, there were 57 (67.1%) TT homozygotes and 28 (32.9%) TC heterozygotes, with the frequency of the minor NPPA:c.2238C allele at 16.5% (28 of 170 alleles). Among the 245 men with HF, there were 182 (74.3%) TT homozygotes, 60 (24.5%) TC heterozygotes, and 3 (1.2%) CC homozygotes, with the frequency of the minor NPPA:c.2238C allele at 13.5% (66 of 490 alleles). There were no significant differences in the frequency distributions of NPPA:rs5065 alleles or genotypes between women and men with HF (p = 0.335 and p = 0.075, respectively).
For the NPPB:rs198389 (c.-381T>C) polymorphism, among the 85 women with HF, there were 24 (28.2%) TT homozygotes, 45 (53.0%) TC heterozygotes, and 16 (19.8%) CC homozygotes, with the frequency of the minor NPPB:c.-381C allele at 45.3% (77 of 170 alleles). Among the 245 men with HF, there were 88 (35.9%) TT homozygotes, 111 (45.3%) TC heterozygotes, and 46 (18.8%) CC homozygotes, with the frequency of the minor NPPB:c.-381C allele at 41.4% (203 of 490 alleles). There were no significant differences in the frequency distributions of NPPB:rs198389 alleles or genotypes between women and men with HF (p = 0.380 and p = 0.171, respectively).
There were also no significant differences in the frequency distributions of NPPA:rs5065 and NPPB:rs198389 genotypes or alleles between patients with HF and control newborns (Table 1).
Except for the frequency of smoking and LVEF values, there were no significant differences in clinical and echocardiographic variables among patients with HF regarding the NPPA:rs5065 (c.2238T>C) polymorphism. The prevalence of smoking in wild-type NPPA:rs5065 homozygotes (TT homozygotes) was significantly higher than that in patients carrying at least one mutated c.2238C allele (TC or CC genotypes). Conversely, the LVEF in patients homozygous for the mutated c.2238C NPPA allele was significantly higher than that in patients carrying at least one wild-type NPPA:rs5065 allele (TT or TC genotypes) (Table 2). However, there were no significant differences in any of the clinical or echocardiographic variables analyzed among patients with HF regarding the NPPB:rs198389 polymorphism (Table 3).
There were no significant differences in the frequency distributions of NPPA:rs5065 and NPPB:rs198389 genotypes or alleles between patients with HF and hypertension and those without hypertension (Table 4). In addition, no association was found between the NPPA:rs5065 and NPPB:rs198389 polymorphisms and left ventricular hypertrophy in the patients with HF (Table 5).
Finally, there were no significant differences in the frequency distributions of NPPA:rs5065 and NPPB:rs198389 genotypes or alleles among the studied patients regarding LVEF-based HF categories (Table 6).

3. Discussion

The results of our study showed no significant differences in the frequency distributions of either polymorphism between patients with HF and healthy newborns as the control group. In addition, within the HF group, there were no significant associations between the NPPA:rs5065 or NPPB:rs198389 genotypes or alleles and the other analyzed variables except for smoking prevalence and LVEF values in relation to NPPA variants. It is worth noting that the NPPA:rs5065 and NPPB:rs198389 polymorphisms were analyzed by us individually. This approach is justified because Newton-Cheh et al. [33] demonstrated in 2009 that there is no linkage disequilibrium between these polymorphisms despite their close proximity on chromosome 1 (chromosomal positions according to GRCh38.p14 Genome assembly: 1:11,846,011 for rs5065 and 1:11,859,214 for rs198389).
The present study has shown that the NPPA:rs5065 and NPPB:rs198389 polymorphisms are not associated with the risk of HF in Polish individuals. The frequencies of the minor alleles (C alleles) of NPPA:rs5065 and NPPB:rs198389 in patients with HF were 14.2% and 42.4%, respectively, and the frequencies in control neonates were 16.0% and 43.4%, respectively.
Larsen et al. [34] emphasized that healthy newborns are a representative sample for estimating the frequency of genetic variants in the general population. Notably, no deviations from Hardy–Weinberg equilibrium were observed in either our control newborns or patients with HF, suggesting no selection bias, population stratification, or genotyping errors [35] in the present study.
The validity of our results—excluding NPPA:rs5065 and NPPB:rs198389 as risk factors for HF—is further supported by an analysis of results from the NHGRI-EBI GWAS Catalog [36]. A search of the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/home, accessed on 11 November 2024) revealed no direct associations between these genetic variants and susceptibility to HF in genome-wide association studies. Similarly, results from a study by Geelhoed et al. [37] did not indicate a significant association between NPPB:rs198389 and HF in individuals from the FINRISK 1997 cohort. Furthermore, Pfister et al. [38] found no association between the c.-381T>C NPPB promoter polymorphism and HF risk in a prospective analysis of the European Prospective Investigation into Cancer and Nutrition (EPIC) Norfolk cohort, which included 23,192 participants. However, the authors did not exclude a potential association of the NPPB:rs198389 variant with specific subgroups of patients with HF, such as those with diabetes or hypertension [39].
By contrast, our study revealed no associations between the NPPA:rs5065 and NPPB:rs198389 polymorphisms and the risk for T2DM or primary hypertension in Polish patients with HF. Interestingly, in 2001, Nannipieri et al. [39] reported a significantly lower frequency of the NPPA:rs5065 mutated allele in Italian individuals with T2DM or hypertension compared with healthy controls in a clinical cohort of 1033 subjects. However, two years later, in 1288 participants from the Mexico City Diabetes Study, the same group found a higher frequency of the c.2238C NPPA allele in hypertensive patients compared with normotensive individuals but no significant differences in the distribution of NPPA:rs5065 genotypes or alleles between patients with T2DM and subjects with normal glucose tolerance [40].
In addition, we previously observed a higher frequency of systolic blood pressure at the ≥90th percentile in Polish newborns carrying the minor c.2238C NPPA allele than in wild-type homozygotes [32]. Conversely, in patients with CAD (n = 1810) from New Zealand, the minor NPPA:rs5065 allele (but not NPPB:rs198389) was associated with a lower history of hypertension [23]. Finally, a meta-analysis by Wang et al. [17] based on 7014 subjects of various ethnic origins from 13 case-control studies, including the Italians analyzed by Nannipieri et al. in 2001 [39], indicated no association between the NPPA:rs5065 polymorphism and the overall risk of primary hypertension.
The results of a meta-analysis based on 49,279 Europeans, including 10,239 subjects from the earlier meta-analysis by Meirhaeghe et al. clearly confirmed a decreased risk of T2DM in individuals homozygous for the minor allele (c.-381C) of the NPPB:rs198389 polymorphism [19]. This association between the NPPB:rs198389 minor variant and a reduced risk of T2DM was further supported by a meta-analysis conducted by Pfister et al. [41], which included a total of 23,382 individuals with diabetes and 57,898 controls, incorporating all subjects analyzed previously in the meta-analysis by Choquet et al. [42]. In addition, Everett et al., using a prospective case-cohort approach within the Women’s Health Study, reported a per-allele hazard ratio for T2DM of 0.92 (95% confidence interval = 0.85–0.99, p = 0.036) for the NPPB:rs198389 polymorphism in an adjusted Cox model [43]. By contrast, Meroufel et al. [44] found no association between NPPB:rs198389 and the risk of T2DM in an Algerian population.
Reports concerning the association of NPPB:rs198389 with blood pressure or hypertension are scarce [23,28,32]. As previously cited, Ellis et al. [23] found no association between the NPPB:rs198389 polymorphism and a lower history of hypertension in New Zealand patients with CAD. However, Musani et al. [28] reported an association between NPPB:rs198389 and systolic blood pressure in Black/African-American individuals as part of the COGENT consortium. In addition, we previously observed in Polish neonates that the frequency of systolic blood pressure at the ≥90th percentile was significantly higher in NPPB:rs198389 CC homozygotes than in those homozygous for the wild-type allele (TT homozygotes) [32].
There are also only a few reports focused on analyzing the association between NPPA:rs5065 and NPPB:rs198389 polymorphisms with LVM or left ventricular hypertrophy [32,45]. In the present study, we found no association between NPPA:rs5065 and LVM in patients with HF, which is consistent with the results of a study conducted in 203 hypertensive Italian individuals [45] and our previous analysis of 206 healthy Polish neonates [32]. However, we also found no association between LVM and NPPB:rs198389 variants, which contrasts with the results of our earlier study in newborns [32] and the findings reported by Musani et al. in White individuals from the EchoGEN consortium [28].
Finally, we found no significant associations between NPPB:rs198389 polymorphisms and LVEF or the LVEF categories defined by Bozkurt et al. [3]. However, the LVEF in patients homozygous for the minor NPPA C allele was significantly higher than in patients carrying at least one wild-type (T) allele. By contrast, Wu et al. [46], in a group of 747 consecutive Southern Han Chinese patients with CAD, found no significant differences in the frequency distributions of NPPA:rs5065 genotypes or alleles between individuals with a reduced LVEF (201 patients with an LVEF of ≤45%) and those with a preserved LVEF (546 patients with an LVEF of >45%).
The major limitations of our study, which reduce the ability to draw reliable conclusions, include differences in the frequencies of both polymorphisms (especially NPPA:rs5065) among various ethnic groups and the relatively small size of the analyzed sample. It should be noted that, of the 13 studies included in the meta-analysis by Wang et al. [17], only the analysis by Rutledge et al. [47] conducted in African Americans revealed an association of NPPA:rs5065 (specifically in the co-dominant model: TC versus TT) with the risk of hypertension. The frequency of the NPPA:rs5065 minor allele in normotensive controls, reported as 38.6% by Rutledge et al. [47], is consistent with its prevalence (41.8%) in individuals of African ancestry from the 1000 Genomes Project (https://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=1:11845511-11846511;v=rs5065;vdb=variation;vf=377, accessed on 15 March 2025). On the other hand, in addition to the study by Rutledge et al. [47], five other studies included in the meta-analysis by Wang et al. [17] had smaller sample sizes than our current report. The simulation we performed for a significant association of the NPPB:rs198389 polymorphism (using the recessive inheritance model for the minor C allele) with hypertension using Open Epi (www.openepi.com), a free open-source software (version 3.01.) for statistical analysis, indicated that the required minimum sample size for 80% statistical power and a 5% type I error rate (α) would be 533 hypertensive patients with HF and 102 normotensive patients with HF (compared with 277 and 53, respectively, in our current study).

4. Materials and Methods

4.1. Patients

Both the eligibility criteria and the recruitment process of patients for our current study have been described in detail previously [1,48]. Briefly, the study group consisted of 330 patients (245 men and 85 women) with chronic HF of NYHA functional class I to IV. This group included 220 patients (170 men and 50 women) with heart failure caused by coronary heart disease, 42 patients (24 men and 18 women) with HF caused by valvular disease, and 68 patients (51 men and 17 women) with HF due to both coronary heart disease and valvular disease. The control group comprised 206 full-term healthy newborns (114 male neonates and 92 female neonates) genotyped for NPPA:rs5065 and NPPB:rs198389 genetic variants in 2015 [32]. All patients with HF underwent transthoracic echocardiography as described previously [1,48], and their clinical and laboratory data were obtained from their medical records. The study protocol was approved by the local bioethics committee at the Pomeranian University in Szczecin, and all recruited HF individuals or parents of all control newborns provided written informed consent to participate in the study. Both patients with HF and control newborns were of Polish nationality, of European descent, and lived in the Polish Western Pomerania region.

4.2. Genotyping

Genomic DNA was isolated from whole blood using the QIAamp Blood DNA Mini Kit (QIAGEN, Hilden, Germany). Genotyping of the NPPA:rs5065 (c.2238T>C) and NPPB:rs198389 (c.-381T>C) polymorphisms was carried out using polymerase chain reaction (PCR)-restriction fragment length polymorphism according to previously described methods [32]. Briefly, amplification of a 132-base pair (bp) NPPA sequence, including the rs5065 polymorphism, was performed by PCR using PCR Master Mix (2X) (Thermo Fisher Scientific, Waltham, MA, USA) with 5′-GGCACACTCATACATGAAGCTGACTTT-3′ as the forward primer and 5′-GCAGTCTGTCCCTAGGCCCA-3′ as the reverse primer. NPPA amplicons were subsequently digested with the ScaI restriction enzyme (Thermo Fisher Scientific), yielding restriction fragments of 78 and 54 bp for the c.2238T allele or remaining uncut for the c.2238C allele. Amplification of a 500-bp NPPB sequence, including the rs198389 polymorphism, was performed by PCR using PCR Master Mix (2X) (Thermo Fisher Scientific) with 5′-GCCGGGGCTGTTTTCGCTGTGAGT-3′ as the forward primer and 5′-CGGAGGCTGCTGCTGCTGCTTCTG-3′ as the reverse primer (both NPPA and NPPB primers were from TIB MOL BIOL, Poznań, Poland). NPPB amplicons were subsequently digested with the EcoRII restriction enzyme (Thermo Fisher Scientific), yielding restriction fragments of 238, 133, 98, and 31 bp for the c.-381T allele or 371, 98, and 31 bp for the c.-381C allele. Restriction products were electrophoretically separated in 3% agarose gels and visualized by staining with Midori Green (Nippon Genetics Europe, Düren, Germany).

4.3. Statistical Analyses

Parameters were compared between groups using the chi-square test or Fisher’s exact test for qualitative variables and the Kruskal–Wallis test or Mann–Whitney test for quantitative variables, as appropriate. Possible deviations of NPPA:rs5065 or NPPB:rs198389 genotype frequencies from the Hardy–Weinberg equilibrium were assessed using Fisher’s exact test. The strength of the association of qualitative variables with genotypes and alleles was described as an odds ratio with a 95% confidence interval. Two-tailed tests with p < 0.05 were considered statistically significant. Calculations were performed using a data analysis software system (Statistica, version 13, TIBCO software, Palo Alto, CA, USA).

5. Conclusions

The results of our study conducted on Polish individuals did not confirm an association between the NPPA:rs5065 and NPPB:rs198389 genetic polymorphisms and predisposition to HF or HF-intermediate phenotypes except for LVEF. These findings further highlight the impact of ethnic background on the prevalence of risk alleles and their potential association with clinical phenotypes.

Author Contributions

Conceptualization, A.C. and I.G.; methodology, A.G.-R., A.C. and I.G.; software, K.S.; validation, M.F. and J.R.; formal analysis, K.S.; investigation, A.G.-R., M.F. and K.L.; data curation, J.R. and K.L.; writing—original draft preparation, A.G.-R., M.F., J.R., K.L., K.S., A.C. and I.G.; writing—review and editing, A.C. and I.G.; supervision, I.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the bioethics committee of the Pomeranian Medical University, Szczecin, Poland (decisions No. KB-00112/87/17 and BN-001/57/05).

Informed Consent Statement

Informed consent was obtained from all HF patients and the parents of all newborns involved in the study.

Data Availability Statement

The data are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ANPA-type Natriuretic Peptide (Arial Natriuretic Peptide)
ARICAtherosclerosis Risk in Communities
BMIBody Mass Index
BNPB-type Natriuretic Peptide
CADCoronary Artery Disease
COGENTClopidogrel and the Optimization of Gastrointestinal Events Trial
EFEjection Fraction
HFHeart Failure
HFmrEFHeart Failure with mildly reduced Ejection Fraction
HfpEFHeart Failure with preserved Ejection Fraction
HFrEFHeart Failure with reduced Ejection Fraction
IVSTInterventricular Septal (Wall) Thickness
LVEDDLeft Ventricular End-Diastolic Diameter
LVEFLeft Ventricular Ejection Fraction
LVHLeft Ventricular Hypertrophy
LVMLeft Ventricular Mass
LVMILeft Ventricular Mass Index
NPNatriuretic Peptide
NPPANatriuretic Peptide A gene
NPPBNatriuretic Peptide B gene
NYHANew York Heart Association
PCRPolymerase Chain Reaction
PWTPosterior Wall Thickness
RFLPRestriction Fragment Length Polymorphism
STOP-HFSt Vincent’s Screening to Prevent Heart Failure
T2DMType 2 Diabetes Mellitus

References

  1. Gorący, I.; Gorący, A.; Kaczmarczyk, M.; Rosik, J.; Lewandowska, K.; Ciechanowicz, A. The Genetic Variants in the Renin-Angiotensin System and the Risk of Heart Failure in Polish Patients. Genes 2022, 13, 1257. [Google Scholar] [CrossRef] [PubMed]
  2. Savarese, G.; Becher, P.M.; Lund, L.H.; Seferovic, P.; Rosano, G.M.C.; Coats, A.J.S. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc. Res. 2023, 118, 3272–3287, Erratum in Cardiovasc. Res. 2023, 119, 1453. [Google Scholar] [CrossRef]
  3. Bozkurt, B.; Coats, A.J.S.; Tsutsui, H.; Abdelhamid, C.M.; Adamopoulos, S.; Albert, N.; Anker, S.D.; Atherton, J.; Böhm, M.; Butler, J.; et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur. J. Heart Fail. 2021, 23, 352–380. [Google Scholar] [CrossRef] [PubMed]
  4. Volpe, M.; Carnovali, M.; Mastromarino, V. The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin. Sci. 2016, 130, 57–77. [Google Scholar] [CrossRef]
  5. Volpe, M.; Gallo, G.; Rubattu, S. Endocrine functions of the heart: From bench to bedside. Eur. Heart J. 2023, 44, 643–655. [Google Scholar] [CrossRef]
  6. Kuwahara, K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacol. Ther. 2021, 227, 107863. [Google Scholar] [CrossRef] [PubMed]
  7. Giovou, A.E.; Gladka, M.M.; Christoffels, V.M. The Impact of Natriuretic Peptides on Heart Development, Homeostasis, and Disease. Cells 2024, 13, 931. [Google Scholar] [CrossRef]
  8. Rubattu, S.; Sciarretta, S.; Marchitti, S.; Bianchi, F.; Forte, M.; Volpe, M. The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. Int. J. Mol. Sci. 2018, 19, 540. [Google Scholar] [CrossRef]
  9. Scarpino, S.; Marchitti, S.; Stanzione, R.; Evangelista, A.; Di Castro, S.; Savoia, C.; Quarta, G.; Sciarretta, S.; Ruco, L.; Volpe, M.; et al. Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J. Hypertens. 2009, 27, 1804–1813. [Google Scholar] [CrossRef]
  10. Greenberg, B.D.; Bencen, G.H.; Seilhamer, J.J.; Lewicki, J.A.; Fiddes, J.C. Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor. Nature 1984, 312, 656–658. [Google Scholar] [CrossRef]
  11. Kato, N.; Sugiyama, T.; Morita, H.; Nabika, T.; Kurihara, H.; Yamori, Y.; Yazaki, Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin. Sci. 2000, 98, 251–258. [Google Scholar] [CrossRef]
  12. Cannone, V.; Huntley, B.K.; Olson, T.M.; Heublein, D.M.; Scott, C.G.; Bailey, K.R.; Redfield, M.M.; Rodeheffer, R.J.; Burnett, J.C., Jr. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: A 9-year follow-up study. Hypertension 2013, 62, 860–865. [Google Scholar] [CrossRef]
  13. Nannipieri, M.; Penno, G.; Pucci, L.; Colhoun, H.; Motti, C.; Bertacca, A.; Rizzo, L.; De Giorgio, L.; Zerbini, G.; Mangili, R.; et al. Pronatriodilatin gene polymorphisms, microvascular permeability, and diabetic nephropathy in type 1 diabetes mellitus. J. Am. Soc. Nephrol. 1999, 10, 1530–1541. [Google Scholar] [CrossRef] [PubMed]
  14. Ciechanowicz, A.; Kurzawski, G.; Widecka, K.; Goździk, J.; Adler, G.; Czekalski, S. Mutacja T-->C nukleotydu 2238 genu prekursora przedsionkowego peptydu natriuretycznego (ANP) i niejednorodność sodowrażliwego nadciśnienia tętniczego. Doniesienie wstepne [Mutation T-->C of nucleotide 2238 in the gene of atrial natriuretic peptide (ANP) precursor and heterogeneity of sodium-sensitive hypertension. Preliminary report]. Pol. Arch. Intern. Med. 1997, 98, 501–509. [Google Scholar]
  15. Vassalle, C.; Andreassi, M.G.; Prontera, C.; Fontana, M.; Zyw, L.; Passino, C.; Emdin, M. Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin. Chem. 2007, 53, 1886–1890. [Google Scholar] [CrossRef] [PubMed]
  16. Wang, J.; Yang, Y.; Zheng, M.; Zhang, L.; Wulasihan, M. Atrial natriuretic peptide T2238C gene polymorphism and the risk of cardiovascular diseases: A meta-analysis. Biomed. Rep. 2024, 20, 41. [Google Scholar] [CrossRef] [PubMed]
  17. Wang, J.; Wang, Z.; Yu, C. Association of Polymorphisms in the Atrial Natriuretic Factor Gene with the Risk of Essential Hypertension: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2016, 13, 458. [Google Scholar] [CrossRef]
  18. Seidelmann, S.B.; Vardeny, O.; Claggett, B.; Yu, B.; Shah, A.M.; Ballantyne, C.M.; Selvin, E.; MacRae, C.A.; Boerwinkle, E.; Solomon, S.D. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J. Am. Heart Assoc. 2017, 6, e005257. [Google Scholar] [CrossRef]
  19. Meirhaeghe, A.; Sandhu, M.S.; McCarthy, M.I.; de Groote, P.; Cottel, D.; Arveiler, D.; Ferrières, J.; Groves, C.J.; Hattersley, A.T.; Hitman, G.A.; et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum. Mol. Genet. 2007, 16, 1343–1350. [Google Scholar] [CrossRef]
  20. Lanfear, D.E.; Stolker, J.M.; Marsh, S.; Rich, M.W.; McLeod, H.L. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc. Drugs Ther. 2007, 21, 55–62. [Google Scholar] [CrossRef]
  21. Takeishi, Y.; Toriyama, S.; Takabatake, N.; Shibata, Y.; Konta, T.; Emi, M.; Kato, T.; Kawata, S.; Kubota, I. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem. Biophys. Res. Commun. 2007, 362, 480–484. [Google Scholar] [CrossRef] [PubMed]
  22. Costello-Boerrigter, L.C.; Boerrigter, G.; Ameenuddin, S.; Mahoney, D.W.; Slusser, J.P.; Heublein, D.M.; Redfield, M.M.; Rodeheffer, R.J.; Olson, T.M.; Burnett, J.C., Jr. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin. Proc. 2011, 86, 210–218, Erratum in Mayo Clin. Proc. 2011, 86, 469. [Google Scholar] [CrossRef]
  23. Ellis, K.L.; Newton-Cheh, C.; Wang, T.J.; Frampton, C.M.; Doughty, R.N.; Whalley, G.A.; Ellis, C.J.; Skelton, L.; Davis, N.; Yandle, T.G.; et al. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J. Mol. Cell Cardiol. 2011, 50, 695–701. [Google Scholar] [CrossRef]
  24. Folkersen, L.; Gustafsson, S.; Wang, Q.; Hansen, D.H.; Hedman, Å.K.; Schork, A.; Page, K.; Zhernakova, D.V.; Wu, Y.; Peters, J.; et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat. Metab. 2020, 2, 1135–1148. [Google Scholar] [CrossRef]
  25. Xhaard, C.; Rouget, R.; Vodovar, N.; Le Floch, E.; Dandine-Roulland, C.; Wagner, S.; Bacq-Daian, D.; Thuillier, Q.; Boivin, J.M.; Branlant, C.; et al. Impact of natriuretic peptide polymorphisms on diastolic and metabolic function in a populational cohort: Insights from the STANISLAS cohort. ESC Heart Fail. 2022, 9, 729–739. [Google Scholar] [CrossRef]
  26. Sun, B.B.; Maranville, J.C.; Peters, J.E.; Stacey, D.; Staley, J.R.; Blackshaw, J.; Burgess, S.; Jiang, T.; Paige, E.; Surendran, P.; et al. Genomic atlas of the human plasma proteome. Nature 2018, 558, 73–79. [Google Scholar] [CrossRef]
  27. Caron, B.; Patin, E.; Rotival, M.; Charbit, B.; Albert, M.L.; Quintana-Murci, L.; Duffy, D.; Rausell, A.; Milieu Intérieur Consortium. Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes. Genome Med. 2022, 14, 28. [Google Scholar] [CrossRef] [PubMed]
  28. Musani, S.K.; Fox, E.R.; Kraja, A.; Bidulescu, A.; Lieb, W.; Lin, H.; Beecham, A.; Chen, M.H.; Felix, J.F.; Fox, C.S.; et al. Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: The Jackson Heart Study. Circ. Cardiovasc. Genet. 2015, 8, 122–130. [Google Scholar] [CrossRef] [PubMed]
  29. Johansson, Å.; Eriksson, N.; Lindholm, D.; Varenhorst, C.; James, S.; Syvänen, A.C.; Axelsson, T.; Siegbahn, A.; Barratt, B.J.; Becker, R.C.; et al. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum. Mol. Genet. 2016, 25, 1447–1456. [Google Scholar] [CrossRef]
  30. Katz, D.H.; Tahir, U.A.; Bick, A.G.; Pampana, A.; Ngo, D.; Benson, M.D.; Yu, Z.; Robbins, J.M.; Chen, Z.Z.; Cruz, D.E.; et al. Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease. Circulation 2022, 145, 357–370. [Google Scholar] [CrossRef]
  31. Cannone, V.; Ledwidge, M.; Watson, C.; McKie, P.M.; Burnett, J.C., Jr.; McDonald, K. STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure. JACC Basic. Transl. Sci. 2021, 6, 497–504. [Google Scholar] [CrossRef] [PubMed]
  32. Gorący, I.; Dawid, G.; Skonieczna-Żydecka, K.; Kaczmarczyk, M.; Łoniewska, B.; Gorący, J. Association of genetic variation in the natriuretic peptide system and left ventricular mass and blood pressure in newborns. Kardiol. Pol. 2015, 73, 366–372. [Google Scholar] [CrossRef]
  33. Newton-Cheh, C.; Larson, M.G.; Vasan, R.S.; Levy, D.; Bloch, K.D.; Surti, A.; Guiducci, C.; Kathiresan, S.; Benjamin, E.J.; Struck, J.; et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat. Genet. 2009, 41, 348–353. [Google Scholar] [CrossRef]
  34. Larsen, T.B.; Lassen, J.F.; Brandslund, I.; Byriel, L.; Petersen, G.B.; Nørgaard-Pedersen, B. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb. Res. 1998, 89, 211–215. [Google Scholar] [CrossRef] [PubMed]
  35. Namipashaki, A.; Razaghi-Moghadam, Z.; Ansari-Pour, N. The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies. Cell J. 2015, 17, 187–192. [Google Scholar] [CrossRef] [PubMed]
  36. Sollis, E.; Mosaku, A.; Abid, A.; Buniello, A.; Cerezo, M.; Gil, L.; Groza, T.; Güneş, O.; Hall, P.; Hayhurst, J.; et al. The NHGRI-EBI GWAS Catalog: Knowledgebase and deposition resource. Nucleic Acids Res. 2023, 51, D977–D985. [Google Scholar] [CrossRef]
  37. Geelhoed, B.; Börschel, C.S.; Niiranen, T.; Palosaari, T.; Havulinna, A.S.; Fouodo, C.J.K.; Scheinhardt, M.O.; Blankenberg, S.; Jousilahti, P.; Kuulasmaa, K.; et al. Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: A Mendelian randomization study in the FINRISK cohort. EP Europace. 2020, 22, 1463–1469. [Google Scholar] [CrossRef]
  38. Pfister, R.; Luben, R.N.; Khaw, K.T.; Wareham, N.J. Common genetic variants of the natriuretic peptide gene locus are not associated with heart failure risk in participants in the EPIC-Norfolk study. Eur. J. Heart Fail. 2013, 15, 624–627. [Google Scholar] [CrossRef]
  39. Nannipieri, M.; Manganiello, M.; Pezzatini, A.; De Bellis, A.; Seghieri, G.; Ferrannini, E. Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertension 2001, 37, 1416–1422. [Google Scholar] [CrossRef]
  40. Nannipieri, M.; Posadas, R.; Williams, K.; Politi, E.; Gonzales-Villalpando, C.; Stern, M.P.; Ferrannini, E. Association between polymorphisms of the atrial natriuretic peptide gene and proteinuria: A population-based study. Diabetologia 2003, 46, 429–432. [Google Scholar] [CrossRef]
  41. Pfister, R.; Sharp, S.; Luben, R.; Welsh, P.; Barroso, I.; Salomaa, V.; Meirhaeghe, A.; Khaw, K.T.; Sattar, N.; Langenberg, C.; et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: Evidence of causal association from population studies. PLoS Med. 2011, 8, e1001112. [Google Scholar] [CrossRef] [PubMed]
  42. Choquet, H.; Cavalcanti-Proença, C.; Lecoeur, C.; Dina, C.; Cauchi, S.; Vaxillaire, M.; Hadjadj, S.; Horber, F.; Potoczna, N.; Charpentier, G.; et al. The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: An updated meta-analysis in 49 279 subjects. Hum. Mol. Genet. 2009, 18, 2495–2501. [Google Scholar] [CrossRef] [PubMed]
  43. Everett, B.M.; Cook, N.R.; Chasman, D.I.; Magnone, M.C.; Bobadilla, M.; Rifai, N.; Ridker, P.M.; Pradhan, A.D. Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin. Chem. 2013, 59, 557–565. [Google Scholar] [CrossRef] [PubMed]
  44. Meroufel, D.N.; Ouhaïbi-Djellouli, H.; Mediene-Benchekor, S.; Hermant, X.; Grenier-Boley, B.; Lardjam-Hetraf, S.A.; Boulenouar, H.; Hamani-Medjaoui, I.; Saïdi-Mehtar, N.; Amouyel, P.; et al. Examination of the brain natriuretic peptide rs198389 single-nucleotide polymorphism on type 2 diabetes mellitus and related phenotypes in an Algerian population. Gene 2015, 567, 159–163. [Google Scholar] [CrossRef]
  45. Rubattu, S.; Bigatti, G.; Evangelista, A.; Lanzani, C.; Stanzione, R.; Zagato, L.; Manunta, P.; Marchitti, S.; Venturelli, V.; Bianchi, G.; et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 2006, 48, 499–505. [Google Scholar] [CrossRef]
  46. Wu, Z.; Xu, M.; Sheng, H.; Lou, Y.; Su, X.; Chen, Y.; Lu, L.; Liu, Y.; Jin, W. Association of natriuretic peptide polymorphisms with left ventricular dysfunction in southern Han Chinese coronary artery disease patients. Int. J. Clin. Exp. Pathol. 2014, 7, 7148–7157. [Google Scholar]
  47. Rutledge, D.R.; Sun, Y.; Ross, E.A. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J. Hypertens. 1995, 13, 953–955. [Google Scholar] [CrossRef]
  48. Gorący, I.; Peregud-Pogorzelska, M.; Safranow, K.; Ciechanowicz, A. Key genetic variants in the renin-angiotensin system and left ventricular mass in a cohort of Polish patients with heart failure. Kardiol. Pol. 2021, 79, 765–772. [Google Scholar] [CrossRef]
Table 1. Frequency distribution of NPPA:rs5065 and NPPB:rs198389 genotypes and alleles in patients with heart failure (HF) and in control newborns.
Table 1. Frequency distribution of NPPA:rs5065 and NPPB:rs198389 genotypes and alleles in patients with heart failure (HF) and in control newborns.
PolymorphismHF Patients
(n = 330)		Control Newborns a (n = 206)p bCompared Genotypes or AllelesOR (95% CI)p a
N(%)n%
NPPA genotype
TT239(72.4)143(69.4)0.678CC + CT vs. TT0.86 (0.59–1.27)0.454
TC88(26.7)60(29.1)CC vs. CT + TT0.62 (0.12–3.10)0.680
CC3(0.9)3(1.5)CC vs. TT0.60 (0.12–3.00)0.676
NPPA allele
T566(85.8)346(84.0)0.427C vs. T0.87 (0.62–1.22)0.427
C94(14.2)66(16.0)
NPPB genotype
TT112(33.9)62(30.1)0.445CC + CT vs. TT0.84 (0.58–1.22)0.356
TC156(47.3)109(52.9)CC vs. CT + TT1.13 (0.71–1.78)0.597
CC62(18.8)35(17.0)CC vs. CT0.98 (0.58–1.64) 0.920
NPPB allele
T380(57.6)233(56.6)0.742C vs. T0.96 (0.75–1.23)0.742
C280(42.4)179(43.4)
a Results previously published in [32]. b chi-square test. Abbreviations: CI, Confidence Interval, HF, Heart Failure; NPPA, Natriuretic Peptide A gene; NPPB, Natriuretic Peptide B gene; OR, Odds Ratio.
Table 2. Characteristics of HF patients in regard to NPPA:rs5065 polymorphism.
Table 2. Characteristics of HF patients in regard to NPPA:rs5065 polymorphism.
VariableNPPA:rs5065 (c.2238T>C) Genotypep ap D bp R b
TT (n = 239)TC (n = 88)CC (n = 3)
Age, years66 (61:70)67 (63:73)68 (67:77)0.1250.0620.270
BMI, kg/m229.0 (25.8:31.8)29.0 (26.0:32.1)29.7 (27.7:33.9)0.7660.7670.526
Males, n (%)182 (76.1)60 (68.2)3 (100.0)0.2040.1990.306
Smokers, n (%)87 (36.4)19 (21.6)1 (33.3)0.0400.0130.973
T2DM, n (%)87 (36.4)30 (34.1)1 (33.3)0.9250.6930.930
Hypertension, n (%)201 (84.1)73 (82.9)3 (100.0)0.7260.8980.447
Echocardiographic parameters:
IVST, cm1.28 (1.10:1.40)1.20 (1.10:1.35)1.10 (1.05:1.90)0.2390.0910.838
PWT, cm1.12 (1.00:1.20)1.12 (1.00:1.22)1.20 (0.90:1.50)0.9010.8640.657
LVEDD, cm5.00 (4.70:5.50)4.90 (4.60:5.20)5.50 (5.20:5.50)0.0840.1060.206
EF, %50.0 (40.0:55.0)45.0 (40.0:55.0)60.0 (55.0:60.0)0.1120.7970.037
LVM, g241.8 (199.6:288.2) (194.2:287.5)229.3 (179.0:281.4)257.0 (187.7:448.7)0.2020.1180.544
LVMI, g/m2124.3 (98.6:148.4)122.9 (92.6:143.5)119.5 (93.7:235.0)0.4560.2430.792
Quantitative variables are presented as median, lower quartile, and upper quartile (Q1:Q3). Qualitative data are presented as a number with corresponding percentage. a Kruskal–Wallis test for quantitative variables and chi2 test for qualitative variables. b Mann–Whitney test for quantitative variables and chi2 test for qualitative variables in dominant (p D) or recessive (p R) mode of inheritance for minor NPPA:rs5065 (c.2238C) allele. Abbreviations: BMI, Body Mass Index; EF, Ejection Fraction; HF, Heart Failure; IVST, Interventricular Septal (Wall) Thickness; LVEDD, left ventricular end-diastolic diameter; LVM, left ventricular mass; LVMI, left ventricular mass index; NPPA, Natriuretic Peptide A gene; PWT, posterior wall thickness; T2DM, type 2 diabetes mellitus.
Table 3. Characteristics of HF patients in regard to NPPB:rs198389 polymorphism.
Table 3. Characteristics of HF patients in regard to NPPB:rs198389 polymorphism.
VariableNPPB:rs198389 (c.-381T>C) Genotypep ap D bp R b
TT (n = 112)TC (n = 156)CC (n = 62)
Age, years66 (62:71)65 (61:71)69 (63:72)0.1650.6590.060
BMI, kg/m228.2 (24.8:31.6)29.7 (26.3:32.5)28.9 (26.8:30.5)0.1120.0580.857
Males, n (%)88 (78.6)111 (71.1)46 (74.2)0.3920.1980.993
Smokers, n (%)32 (28.6)57 (36.5)18 (29.0)0.3190.2840.527
T2DM, n (%)41 (36.6)53 (34.0)24 (38.7)0.7850.8180.591
Hypertension, n (%)92 (82.1)128 (82.0)57 (91.9)0.1640.5250.058
Echocardiographic parameters:
IVST, cm1.30 (1.10:1.40)1.20 (1.10:1.39)1.23 (1.11:1.40)0.5710.8620.358
PWT, cm1.11 (1.00:1.20)1.15 (1.00:1.20)1.12 (1.05:1.20)0.7620.7710.462
LVEDD, cm5.00 (4.70:5.50)5.00 (4.60:5.50)5.0 (4.70:5.50)0.9330.8380.715
EF, %45.0 (40.0:55.0)50.0 (40.0:55.0)45.0 (40.0:55.0)0.8060.5150.886
LVM, g239.9 (190.9:286.3)241.8 (195.1:281.5)236.3 (198.1:304.3)0.7460.8080.444
LVMI, g/m2121.4 (97.1:148.0)122.8 (98.2:147.4)133.5 (107.2:157.6)0.4020.6500.177
Quantitative variables are presented as median, lower quartile, and upper quartile (Q1:Q3). Qualitative data are presented as a number with corresponding percentage. a Kruskal–Wallis test for quantitative variables and chi2 test for qualitative variables. b Mann–Whitney test for quantitative variables and chi2 test for qualitative variables in dominant (p D) or recessive (p R) mode of inheritance for minor NPPA:rs5065 (c.-381C) allele. Abbreviations: BMI, Body Mass Index; EF, Ejection Fraction; HF, Heart Failure; IVST, Interventricular Septal (Wall) Thickness; LVEDD, left ventricular end-diastolic diameter; LVM, left ventricular mass; LVMI, left ventricular mass index; NPPB, Natriuretic Peptide B gene; PWT, posterior wall thickness; T2DM, type 2 diabetes mellitus.
Table 4. An association of NPPA:rs5065 and NPPB:rs198389 polymorphisms with hypertension (HT) in patients with heart failure (HF).
Table 4. An association of NPPA:rs5065 and NPPB:rs198389 polymorphisms with hypertension (HT) in patients with heart failure (HF).
PolymorphismHF Patients with HT
(n = 277)		HF Patients Without HT
(n = 53)		p aCompared Genotypes or AllelesOR (95% CI) for HTp a
n(%)n(%)
NPPA genotype
TT 201(72.6)38(71.7)0.725CC + CT vs. TT0.96 (0.50–1.84)0.897
TC73(26.3)15(28.3)CC vs. CT + TT--
CC3(1.1)0(0.0)CC vs. TT--
NPPA allele
T475(85.7)91(85.8) C vs. T1.39 (0.56–1.83)0.977
C79(14.3)15(14.2)
NPPB genotype
TT92(33.2)20(37.7)0.163CC + CT vs. TT0.22 (0.66–2.24)0.524
TC128(46.2)28(52.8)CC vs. CT + CT2.49 (0.95–6.53)0.057
CC57(20.6)5(9.5)CC vs. TT2.48 (0.88–6.97)0.077
NPPB allele
T312(56.3)68(64.2) C vs. T1.39 (0.90–2.13)0.134
C242(43.7)38(35.8)
a Chi-square test. Abbreviations: CI, Confidence Interval; HF, Heart Failure; HT, Hypertension; NPPA, Natriuretic Peptide A gene; NPPB, Natriuretic Peptide B gene; OR, Odds Ratio.
Table 5. An association of NPPA:rs 5065 and NPPB:rs198389 polymorphisms with left ventricular hypertrophy (LVH) in patients with heart failure (HF).
Table 5. An association of NPPA:rs 5065 and NPPB:rs198389 polymorphisms with left ventricular hypertrophy (LVH) in patients with heart failure (HF).
PolymorphismHF Patients with LVH
(n = 214)		HF Patients Without LVH
(n = 116)		p aCompared Genotypes or AllelesOR (95% CI) for LVHp a
n(%)n(%)
NPPA genotype
TT 156(72.9)83(71.5)0.960CC + CT vs. TT0.93 (0.56–1.55)0.973
TC56(26.2)32(27.6)CC vs. CT + TT1.08 (0.10–12.09)0.947
CC2(0.9)1(0.9)CC vs. TT1.06 (0.09–11.91)0.959
NPPA allele
T368(86.0)198(85.3) C vs. T0.95 (0.60–1.50)0.823
C60(14.0)34(14.7)
NPPB genotype
TT71(33.2)41(35.3)0.700CC + CT vs. TT1.10 (0.68–1.77)0.691
TC100(46.7)56(48.3)CC vs. CT + CT1.28 (0.71–2.33)0.409
CC43(20.1)19(16.4)CC vs. TT1.31 (0.67–2.53)0.428
NPPB allele
T242(56.5)138(59.4) C vs. T1.27 (0.67–2.38)0.461
C186(43.4)94(40.5)
a Chi-square test. Abbreviations: CI, Confidence Interval, HF, Heart Failure; LVH, Left Ventricular Hypertrophy; NPPA, Natriuretic Peptide A gene; NPPB, Natriuretic Peptide B gene; OR, Odds Ratio.
Table 6. An association of NPPA:rs5065 and NPPB:rs198389 polymorphisms in HF patients in regard to EF-based HF category.
Table 6. An association of NPPA:rs5065 and NPPB:rs198389 polymorphisms in HF patients in regard to EF-based HF category.
PolymorphismHFpEF
(n = 167)		HFmrEF
(n = 53)		HFrEF
(n = 110)		p ap a
HFpEF vs. Others		p a
HFrEF vs. Others		p a
HFpEF vs. HFrEF
n(%)n(%)n(%)TT vs. TC vs. CC
C+ vs. Others
CC vs. Others		TT vs. TC vs. CC
C+ vs. Others
CC vs. Others		TT vs. TC vs. CC
C+ vs. Others
CC vs. Others		TT vs. TC vs. CC
C+ vs. Others
CC vs. Others
NPPA genotype
TT122(73.1)36(67.9)81(73.6)0.4280.1980.4630.365
TC42(25.1)17(32.1)29(26.4)0.7220.7950.7270.915
CC3(1.8)0(0.0)0(0.0)0.2280.0860.2660.157
NPPA allele
T286(85.6)89(84.0)191(86.8)0.7840.9240.5810.692
C48(14.4)17(16.0)29(13.2)
NPPB genotype
TT52(31.1)21(39.6)39(35.5)0.5090.2990.8890.613
TC86(51.5)20(37.7)50(45.4)0.4820.2770.6810.454
CC29(17.4)12(22.7)21(19.1)0.6890.5030.9210.715
NPPB allele
T190(56.9)62(58.5)128(58.2)0.9350.7170.9140.763
C144(43.1)44(41.5)92(41.8)
a Chi-square test. Abbreviations: EF, Ejection Fraction; HF, Heart Failure; HFmrEF, HF with mildly reduced Ejection Fraction; HFpEF, HF with preserved Ejection Fraction; HfrEF, HF with reduced Ejection Fraction; NPPA, Natriuretic Peptide A gene; NPPB, Natriuretic Peptide B gene.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gorący-Rosik, A.; Fic, M.; Rosik, J.; Lewandowska, K.; Safranow, K.; Ciechanowicz, A.; Gorący, I. The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients. Int. J. Mol. Sci. 2025, 26, 4567. https://doi.org/10.3390/ijms26104567

AMA Style

Gorący-Rosik A, Fic M, Rosik J, Lewandowska K, Safranow K, Ciechanowicz A, Gorący I. The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients. International Journal of Molecular Sciences. 2025; 26(10):4567. https://doi.org/10.3390/ijms26104567

Chicago/Turabian Style

Gorący-Rosik, Anna, Mateusz Fic, Jakub Rosik, Klaudyna Lewandowska, Krzysztof Safranow, Andrzej Ciechanowicz, and Iwona Gorący. 2025. "The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients" International Journal of Molecular Sciences 26, no. 10: 4567. https://doi.org/10.3390/ijms26104567

APA Style

Gorący-Rosik, A., Fic, M., Rosik, J., Lewandowska, K., Safranow, K., Ciechanowicz, A., & Gorący, I. (2025). The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients. International Journal of Molecular Sciences, 26(10), 4567. https://doi.org/10.3390/ijms26104567

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop